Analyst Ami Fadia from Needham maintained a Buy rating on Axsome Therapeutics and keeping the price target at $150.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia has given his Buy rating due to a combination of factors that highlight the potential of Axsome Therapeutics’ late-stage pipeline. The recent R&D day provided insights into the clinical rationale and market positioning of Axsome’s advanced pipeline assets, which were discussed by various key opinion leaders.
Fadia sees significant upside potential for Axsome, particularly with the planned label expansion for Auvelity into ADA and the submission of a supplemental new drug application in the third quarter of 2025. Additionally, several other late-stage assets are expected to drive substantial growth, with management’s peak sales estimates suggesting a potential increase in topline revenue to over $16 billion.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AXSM in relation to earlier this year.